Author: Benzinga Newsdesk | January 25, 2024 05:07pm
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly sales of $157.10 million which beat the analyst consensus estimate of $154.91 million by 1.42 percent. This is a 12.86 percent increase over sales of $139.20 million the same period last year.